Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Sucralfate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Sucrate এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Duodenal ulcer, gastric ulcer and chronic gastritis. Adults: the usual dose is 2 g of Sucralfate twice daily, taken on rising and at bedtime, or 1 g four times a day, taken 1 hour before meals and at bedtime. The maximum daily dose is 8 g, though treatment for up to twelve weeks may be needed in resistant cases. Children: the safety and efficacy of Sucralfate in children under 14 years of age have not been established. Elderly: there are no special dosage requirements for elderly patients, but as with all medicines the lowest effective dose should be used. Prevention of gastrointestinal bleeding from stress ulceration. Adults: the usual dose is 1 g of Sucralfate, given by mouth or through a nasogastric tube, 4 to 6 times a day. To prevent the nasogastric tube from clogging, flush it with 10 ml of water after each dose. The length of preventive treatment must be decided for each patient. Treatment should continue for as long as one or more risk factors for stress ulceration remain, but normally for no more than 14 days. Sucralfate should be taken on an empty stomach. Antacids should not be given within 30 minutes of a Sucralfate dose.
পার্শ্বপ্রতিক্রিয়া
The most common side effect reported was headache (3.4%), followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhoea (1.1%), and urticaria (hives) (1.1%). Most patients who developed bezoars either had an underlying medical condition that can predispose to bezoar formation (such as delayed gastric emptying) or were receiving enteral tube feeding at the same time. Episodes of hyperglycaemia (high blood sugar) have been reported in diabetic patients.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Ralfate should be used with caution in patients with reduced kidney function, because more aluminium may be absorbed. Ralfate is not recommended for people on dialysis. In patients with severe or long-standing kidney impairment, Ralfate should be used with extreme caution and only for short-term treatment. Small amounts of aluminium are absorbed through the digestive tract, and aluminium may build up in the body. Aluminium-related bone disease (osteodystrophy and osteomalacia), brain disorder (encephalopathy) and anaemia have been reported in patients with chronic kidney impairment. For patients with reduced kidney function, periodic laboratory tests, including aluminium, phosphate, calcium and alkaline phosphatase, are recommended because aluminium is not cleared properly. Taking other aluminium-containing medicines at the same time is not recommended, as this increases the potential for aluminium absorption and toxicity. Bezoars (hardened masses in the stomach) have been reported after Ralfate was given, mainly to severely ill patients in intensive care units. Most of these patients (including newborns, in whom Ralfate is not recommended) had underlying conditions that may make bezoar formation more likely, such as delayed stomach emptying caused by surgery, drug therapy or diseases that slow gut movement, or were also receiving feeding through an enteral tube.
নিষেধাজ্ঞা
Sucralfate tablets and suspension should not be used in patients who are hypersensitive to sucralfate.